Molecular profiling panels for breast cancer – pro
Contemporary breast cancer management uses multigene expression assays to personalise chemoendocrine prescription for those with early-stage ER+/HER2 disease. THis requires multi-gene panels. NCCN recommends this testing.
Davey MG, Kerin MJ. Molecular profiling in contemporary breast cancer management. Br J Surg. 2023 Jun 12;110(7):743-745.
Hitomi Kawaji, Makoto Kubo et al, Comprehensive molecular profiling broadens treatment options for breast cancer patients. Cancer Medicine Volume10, Issue 2 January 2021 Pages 529-539
NCCN BINV-!, 6 of 14, 2024